超声引导下^(125)I放射性粒子植入治疗前列腺癌疗效观察  

Treatment response of permanent ^(125)I seeds implantation brachytherapy for prostate cancer under the guidance of ultrasound

作　　者：詹嘉 常才 陈悦[3] 徐骏[4] 丁海庸[4] 

机构地区：[1]复旦大学附属肿瘤医院超声科,在职硕士生200032 [2]复旦大学上海医学院肿瘤学系,200032 [3]复旦大学附属华东医院超声科 [4]复旦大学附属华东医院泌尿科,200040

出　　处：《上海医学影像》2011年第4期261-264,共4页Shanghai Medical Imaging

摘　　要：目的探讨超声引导下经会阴穿刺植入125I放射性粒子治疗前列腺癌的疗效。方法 40例前列腺癌患者在直肠超声引导下行经会阴125I粒子植入术。其中29例行单纯粒子治疗,11例术后加外放疗。首先对前列腺进行超声扫描,将图像传送到计算机制定种植治疗计划,并在种植前计算放射线对前列腺体积的有效覆盖,以患者血前列腺特异性抗原(prostate-specific antigen,PSA)作为疗效评价标准。结果粒子植入术前和术后各时期PSA值相比明显下降(差异均有显著统计学意义,P≤0.01),其中10人14次出现PSA反弹,而单纯粒子组与联合治疗患者组PSA反弹发生率差异无统计学意义(22.2%vs 27.3%)。结论超声引导经会阴125I放射性粒子植入治疗前列腺癌具有安全、微创、并发症发生率低等优点。Objective To assess the efficacy of permanent ^125Ⅰ brachytherapy in patients with prostate cancer under the guidance of ultrasound. Methods Totally, 40 prostate cancer patients underwent transpermeal ^125Ⅰ seeds implantation brachytherapy under the guidance of transrectal ultrasound. Among them, 11 patients of them also received external beam brachytherapy （ERBT）. Prostate-specific antigen （PSA） was used as the reference standard to evaluate the treatment response. Results The PSA level of patients continuously decreased after radiation for patients with prostate cancer. There were significant differences of PSA between preoperation and every follow-up period after brachytheraphy. And there were ^125Ⅰ patients with 14 times PSA rebounce. There was no significant difference of PSA rebounce rate between two groups （22.2% for single ^125Ⅰ brachytherapy group vs 27.3% fbr combined treatment group）. Conclusions Brachytherapy with transperine;d ^125Ⅰ seeds implantation guided by transrectal ultrasound is a safe, uxinimaily invasive and effective treatment for patients with prostate cancer.

关 键 词：125I放射性粒子 经直肠超声 前列腺癌 前列腺特异性抗原反弹 

分 类 号：R730.55[医药卫生—肿瘤]